How Should Gastric Intestinal Metaplasia Be Managed?

Why the baseline examination matters

A pathology report that simply says 'intestinal metaplasia' is not enough to determine risk. The endoscopy should be reviewed for quality, lesion recognition and whether systematic gastric biopsies adequately sampled the antrum/incisura and corpus. Visible abnormalities should be targeted separately. High-definition white-light inspection plus image enhancement can help identify subtle metaplastic or dysplastic change.

H. pylori is a modifiable risk factor

All patients with GIM should be assessed for H. pylori and treated if positive, with confirmation of eradication. Eradication cannot erase all established cancer risk once metaplasia is present, but it addresses an important carcinogenic driver and is a core part of management.

Risk stratification determines surveillance

Risk is higher with extensive rather than antrum-limited metaplasia, incomplete-type metaplasia, a first-degree family history of gastric cancer, persistent H. pylori, autoimmune gastritis, and origin from or long residence in a region with high gastric-cancer incidence. The 2025 ACG guideline provides a structured framework for selecting higher-risk patients for surveillance rather than applying one interval to everyone.

Dysplasia changes the problem

Once dysplasia is suspected or identified, management should move beyond routine GIM surveillance. Pathology review by an experienced gastrointestinal pathologist and careful repeat high-quality endoscopy are often appropriate. Visible dysplastic lesions should be assessed for endoscopic resection at a center with appropriate expertise.

A practical clinical approach

1. Confirm that the baseline endoscopy and biopsy mapping were adequate.
2. Test for H. pylori, treat if present and document eradication.
3. Determine extent of GIM and review pathology for dysplasia and, when reported, complete versus incomplete subtype.
4. Assess family history, ethnicity/geographic background, autoimmune gastritis and other risk modifiers.
5. Discuss surveillance with higher-risk patients; avoid automatic surveillance in genuinely low-risk GIM.
6. Escalate dysplasia or visible lesions to expert pathology review and advanced endoscopic assessment.

Common errors to avoid

• Treating every GIM diagnosis as carrying the same cancer risk.
• Scheduling surveillance before confirming H. pylori eradication and baseline exam quality.
• Using random biopsies as a substitute for careful mucosal inspection.
• Failing to distinguish GIM from dysplasia, which requires a different management pathway.

What should trainees remember?

GIM is a risk marker, not a cancer diagnosis. The essential skills are high-quality endoscopy, H. pylori eradication and risk stratification.

Free further reading from Dr. Alan B. R. Thomson

Dr. Thomson's Best Practice Guidelines in Gastroenterology Disorders and Endoscopy and Diagnostic Imaging are the most relevant free companion texts.

Frequently asked questions

Does every patient with GIM need surveillance endoscopy?

No. Surveillance should be individualized according to extent and other gastric-cancer risk factors.

Should H. pylori be treated if GIM is already present?

Yes. Test, treat and confirm eradication.

What finding is most concerning?

Dysplasia or a visible suspicious lesion should prompt expert review and an endoscopic resection-oriented assessment rather than routine surveillance alone.

References

1. Thomson ABR. Best Practice Guidelines in Gastroenterology Disorders. CAPstone Academic Publishers; 2024. ISBN 979-8398710120.

2. Thomson ABR. Endoscopy and Diagnostic Imaging, Parts I-II. CAPstone Academic Publishers; 2012. ISBN 978-1477400579 and 978-1477400654.

3. Morgan DR, et al. ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions. American College of Gastroenterology; 2025.

4. American College of Gastroenterology. Guideline Highlights: Diagnosis and Management of Gastric Premalignant Conditions. 2025.